Ironwood Pharmaceuticals Inc (IRWD) Stock Analysis

Verdict: WATCH (do not buy)

Strong LINZESS cash flow fuels cheap 5.6x P/E valuation, but negative equity and a looming 2029 patent cliff cap long-term upside.

Investment score: 56/100

Analysis as of 2026-09-17

Is Ironwood Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis

Ironwood presents a tactical cash-flow value play hampered by long-term patent cliff risks and negative stockholders' equity.

7-factor investment score

Valuation: 75/100 (weight 20%)
Financial Health: 55/100 (weight 15%)
Technical Momentum: 65/100 (weight 15%)
Earnings Quality: 35/100 (weight 15%)
Insider Sentiment: 20/100 (weight 10%)
Analyst Consensus: 70/100 (weight 10%)
Risk-Adjusted Return: 60/100 (weight 15%)

Ironwood Pharmaceuticals Inc opportunities and risks

What speaks for IRWD

High cash generation trading at compressed valuation metrics

What speaks against IRWD

Looming 2029 LINZESS patent cliff and revenue contraction

Peers and competitors

DSGN
ANNX
GYRE
NVCT
AURA

Trailing-twelve-month ratios
Ticker	P/E	P/S	EV/EBITDA	Gross margin	Net margin	FCF yield
IRWD	5.6x	1.9x	4.3x	99.8%	33.4%	25.5%
DSGN	n/a	0.0x	n/a	0.0%	0.0%	-7.1%
ANNX	n/a	0.0x	n/a	0.0%	0.0%	-28.9%
GYRE	n/a	6.7x	n/a	94.3%	-14.5%	-2.1%
NVCT	n/a	0.0x	n/a	0.0%	0.0%	-3.4%
AURA	n/a	0.0x	n/a	0.0%	0.0%	-15.0%
Peer median	n/a	0.0x	n/a	0.0%	0.0%	-7.1%

Frequently asked questions about Ironwood Pharmaceuticals Inc (IRWD)

Is IRWD stock a good investment?

The TradeMates model rates Ironwood Pharmaceuticals Inc as WATCH (do not buy) with an investment score of 56/100. Ironwood presents a tactical cash-flow value play hampered by long-term patent cliff risks and negative stockholders' equity. This is algorithmic model output, not personal investment advice.

Is IRWD stock a buy?

The TradeMates model verdict for IRWD is WATCH (do not buy) with an investment score of 56/100. Treat this as a model signal to review, not a personal buy recommendation.